FGL2在肾透明细胞癌中的表达及其临床意义

The expression and significance of fibrinogen-like protein 2 in patients with clear cell renal cell carcinoma

目的探讨纤维蛋白原样蛋白2(FGL2)在肾透明细胞癌(ccRCC)中的表达及临床意义。方法采用免疫组织化学法检测103例ccRCC患者肿瘤组织及40例癌旁组织中FGL2的表达,分析FGL2的表达与患者临床病理参数及预后的关系。结果FGL2在肾癌组织中呈阳性表达,高表达率明显高于癌旁组织,差异具有统计学意义(62.1%vs.0.0%,χ~2=44.990,P<0.01);FGL2的表达与肿瘤大小(P=0.039)、T分期(P=0.049)、TNM临床分期(P=0.043)显著相关;高表达FGL2患者的总体生存期(OS)及无病生存期(DFS)短于低表达患者(P<0.05);在早期患者(Ⅰ~Ⅱ期)中同样观察到高表达FGL2者的OS及DFS短于低表达患者(P<0.05)。单因素及多因素COX回归分析显示FGL2是患者预后的独立危险因素。结论 FGL2与肾癌的发生发展密切相关,癌组织中FGL2高水平表达提示不良预后,有可能作为肾癌患者判断预后的一种生物标记物,对肾癌提供新的治疗靶点。

Objective To investigate the expression of fibrinogen-like protein 2（FGL2）in patients with clear cell renal cell carcinoma（ccRCC）and to evaluate its clinical significance.Methods Immunohistochemistry was conducted to characterize the expression pattern of FGL2 in 103 archived paraffin-embedded ccRCC and 40 adjacent normal specimens.The relationship of FGL2 protein expression with clinical pathological parameters and prognosis was analyzed.Results The expression of FGL2 protein was significantly higher in ccRCC tissues than in adjacent normal tissues（62.1% vs.0.0%,χ2=44.990,P〈0.01）.High level of FGL2 expression was associated with tumor size（P=0.039）,T classification（P=0.049）and TNM clinical stages（P=0.043）.High FGL2 level was associated with poor overall survival（OS）and disease-free survival（DFS）both in all cases and early stage（Ⅰ~Ⅱ）cases（P〈0.05）.Univariate and multivariate Cox regression analyses showed that FGL2 was an independent prognostic adverse factor for patients with ccRCC.Conclusions Our results suggest that FGL2 is involved in the development and progression of ccRCC,and high FGL2 level predicts poor clinical outcome,which may be used as a useful prognostic marker and an effective target for ccRCC treatment.